FDA Reform Bill May Be Delayed Until September; FDA Holds Tight On Staffing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Reauthorization of prescription drug user fees will go down to the wire as health leaders in House and Senate devote attention to child health legislation.